Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Hyperuricemia

Interventions

DRUG

Rasburicase (SR29142)

Trial Locations (4)

Sanofi-Aventis Administrative Office, Diegem

Sanofi- Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan